Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
RecruitingOBSERVATIONAL
Enrollment
150
Participants
Timeline
Start Date
November 1, 2022
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
Conditions
Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on EchoHealthy Individuals With no Cardiopulmonary Disease
Trial Locations (1)
37232
RECRUITING
Vanderbilt University Medical Center, Nashville
All Listed Sponsors
lead
Vanderbilt University Medical Center
OTHER
NCT05584722 - Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals | Biotech Hunter | Biotech Hunter